Table 4.
Univariate Cox proportional hazard regression analysis of clinicopathological features and immunological markers with disease-free survival (DFS) and Overall Survival (OS) in 63 patients with LA-NPC at the time of presentation
| Relapse | DFS | Death | OS | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | + | HR | 95% CI | *P | – | + | HR | 95% CI | *P | |||
| Age | ||||||||||||
| 40 years | 17 (74)♣ | 6 (26) | 1 | 21 (91) | 2 (9) | 1 | ||||||
| ≥ 40 years | 25 (62) | 15 (38) | 1.47 | 0.57–3.8 | 0.424 | 32 (80) | 8 (20) | 2.0 | 0.42–9.70 | 0.383 | ||
| WHO Type | ||||||||||||
| III | 42 (72) | 16 (28) | 1 | 50 (86) | 8 (14) | 1 | ||||||
| I & II | 0 (0) | 5 (100) | 4.0 | 1.42–11.4 | 0.008 | 3 (60) | 2 (40) | 1.0 | 0.12–8.1 | 0.999 | ||
| T stage | ||||||||||||
| 1&2 | 18 (86) | 3 (14) | 1 | 0.125 | 21 (100) | 0 (0) | 1 | 0.988 | ||||
| 3 | 9 (56) | 7 (44) | 1&2 vs 3 | 3.7 | 1.0–14.4 | 0.058 | 13 (81) | 3 (19) | 1&2 vs 3 | 133,198 | 0.0–6.45E+ 140 | 0.941 |
| 4 | 15 (58) | 11 (42) | 1&2 vs 4 | 3.5 | 1.1–12.5 | 0.057 | 19 (73) | 7 (27) | 1&2 vs 4 | 120,743 | 0.0–5.84E+ 140 | 0.941 |
| N stage | ||||||||||||
| 0&1 | 9 (69) | 4 (31) | 1 | 0.698 | 11 (85) | 2 (15) | 1 | 0.372 | ||||
| 2 | 10 (56) | 8 (44) | 0&1 vs 2 | 1.5 | 0.45–5.0 | 0.501 | 13 (72) | 5 (28) | 0&1 vs 2 | 3.1 | 0.36–26.7 | 0.307 |
| 3 | 23 (72) | 9 (28) | 0&1 vs 3 | 1.0 | 0.32–3.4 | 0.947 | 29 (91) | 3 (9) | 0&1 vs 3 | 1.3 | 0.13–12.2 | 0.843 |
| UICC Stage | ||||||||||||
| III | 9 (64) | 5 (36) | 1 | 11 (79) | 3 (21) | 1 | ||||||
| IVa | 33 (67) | 16 (33) | 0.9 | 0.37–2.9 | 0.898 | 42 (86) | 7 (14) | 0.5 | 0.12–2.0 | 0.328 | ||
| Total TIL | ||||||||||||
| High | 29 (83) | 6 (17) | 1 | 33 (94) | 2 (6) | 1 | ||||||
| Low | 13 (46) | 15 (54) | 4.0 | 1.2–10.7 | 0.008 | 20 (71) | 8 (29) | 4.0 | 0.82–19.2 | 0.087 | ||
| CD3+ TIL | ||||||||||||
| High | 32 (89) | 4 (11) | 1 | 35 (97) | 1 (3) | 1 | ||||||
| Low | 10 (37) | 17 (63) | 8.5 | 3.1–29.6 | < 0.001 | 18 (67) | 9 (33) | 13.1 | 1.64–100 | 0.015 | ||
| CD8+ TIL | ||||||||||||
| High | 35 (80) | 9 (20) | 1 | 42 (95) | 2 (5) | 1 | ||||||
| Low | 7 (37) | 12 (63) | 3.7 | 1.5–8.8 | 0.004 | 11 (58) | 8 (42) | 7.6 | 1.6–37.0 | 0.011 | ||
| FOXP3+/CD3+ | ||||||||||||
| Low (≤ 10% of CD3 + TIL) | 30 (73) | 11 (27) | 1 | 37 (90) | 4 (10) | 1 | ||||||
| High (> 10% of CD3 + TIL) | 12 (55) | 10 (46) | 1.6 | 0.7–3.8 | 0.287 | 16 (73) | 6 (27) | 1.8 | 0.5–7.5 | 0.376 | ||
| ⋄PD-1 +/CD3+ TIL | ||||||||||||
| Low (< 10% of CD3 + TIL) | 16 (62) | 10 (38) | 1 | 22 (85) | 4 (15) | 1 | ||||||
| High (≥ 10% of CD3 + TIL) | 24 (71) | 10 (29) | 0.6 | 0.2–1.5 | 0.260 | 29 (85) | 6 (15) | 0.60 | 0.2–1.5 | 0.260 | ||
| PD-L1 in Tumor (mem or cyto)║ | ||||||||||||
| Positive (≥ 10%) | 32 (71) | 13 (29) | 1 | 12 (67) | 6 (33) | 1 | ||||||
| Negative (< 10%) | 10 (56) | 8 (44) | 1.6 | 0.7–3.8 | 0.315 | 41 (91) | 4 (9) | 3.1 | 0.8–11.49 | 0.100 | ||
| PD-L1 in Tumor (cyto) | ||||||||||||
| Positive (≥ 10%) | 22 (69) | 10 (31) | 1 | 25 (81) | 6 (19) | 1 | ||||||
| Negative (< 10%) | 20 (65) | 11 (35) | 1.1 | 0.4–2.5 | 0.919 | 28 (88) | 4 (12) | 1.3 | 0.34–4.9 | 0.702 | ||
Abbreviations: (+ and -) are number of positive and negative patients, *P values in bold represent significant data, ♣Numbers between brackets are the percentages of patients, ⋄Three samples had unknown PD-1 status. ║ mem membranous, cyto cytoplasmic